[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533964":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":42,"responsibleParty":121,"collaborators":10,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":125,"sex":131,"minAge":132,"maxAge":10,"enrollmentInfo":133,"targetDuration":10,"studyType":136,"phases":10,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Carlos Simon Foundation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cases group",null,"Women recruited between 9 and 15 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy.",[13],"Procedure: Maternal-fetal interface biopsy and peripheral blood collection in cases group",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","Women recruited between 9 and 15 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy",[18],"Procedure: Maternal-fetal interface biopsy and peripheral blood collection in control group",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"PROCEDURE","Maternal-fetal interface biopsy and peripheral blood collection in cases group","Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Maternal-fetal interface biopsy and peripheral blood collection in control group","Maternal-fetal interface tissue (chorionic villi and decidua) will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.",[15],[30],{"name":31,"affiliation":32,"role":33},"Tamara Garrido, PhD","Fundación Carlos Simon para la investigación en salud de la mujer","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Carla Gómez, BSc, MSc","CONTACT","+34962938210","cgomez@fundacioncarlossimon.com",{"name":41,"role":37,"phone":10,"phoneExt":10,"email":10},"Carlos Simón, MD, PhD",[43,60,77,90,105],{"facility":44,"status":45,"city":46,"state":46,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hospital General Universitario Dr. Balmis","RECRUITING","Alicante","Spain","ES",{"type":50,"coordinates":51},"Point",[52,53],-0.48149,38.34517,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":58,"phoneExt":10,"email":59},"Ana María Palacios Marqués","965 93 30 00","ana.palacios.marques@gmail.com",{"facility":61,"status":62,"city":63,"state":63,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Hospital Universitario de Torrejón","NOT_YET_RECRUITING","Madrid",{"type":50,"coordinates":65},[66,67],-3.70256,40.4165,{"lat":67,"lon":66},[70,74],{"name":71,"role":37,"phone":72,"phoneExt":10,"email":73},"Maria del Mar Gil Mira","+34 916 26 26 26","mmar1984@gmail.com",{"name":75,"role":76,"phone":10,"phoneExt":10,"email":10},"Belén Santacruz Martín","SUB_INVESTIGATOR",{"facility":78,"status":45,"city":79,"state":79,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Hospital Clinico Universitario Virgen de la Arrixaca","Murcia",{"type":50,"coordinates":81},[82,83],-1.13004,37.98704,{"lat":83,"lon":82},[86],{"name":87,"role":37,"phone":88,"phoneExt":10,"email":89},"Juan Luis Delgado","+34 968 36 96 74","juanluisdelgado@tokos.org",{"facility":91,"status":45,"city":92,"state":92,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Hospital Universitario de Canarias","Santa Cruz de Tenerife",{"type":50,"coordinates":94},[95,96],-16.25462,28.46824,{"lat":96,"lon":95},[99,103],{"name":100,"role":37,"phone":101,"phoneExt":10,"email":102},"Mercedes Hernández Suárez","922 67 80 00","mercedes021281@hotmail.com",{"name":104,"role":76,"phone":10,"phoneExt":10,"email":10},"Walter Plasencia Acevedo",{"facility":106,"status":45,"city":107,"state":107,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Hospital Universitario y Politécnico La Fe","Valencia",{"type":50,"coordinates":109},[110,111],-0.37966,39.47391,{"lat":111,"lon":110},[114,118],{"name":115,"role":37,"phone":116,"phoneExt":10,"email":117},"Rogelio Monfort Ortiz","+34 961 24 40 00","monfort_isaort@gva.es",{"name":119,"role":37,"phone":116,"phoneExt":10,"email":120},"Beatriz Marcos Puig","marcos_bea@gva.es",{"type":122,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100533964","molecular-study-of-the-maternal-fetal-interface-in-preeclampsia-100533964",false,"NCT06232668","Molecular Study of the Maternal-fetal Interface in Preeclampsia.","Molecular Study of the Maternal-fetal Interface Prospectively to the Onset of Preeclampsia Using Single Cell Technology.","PREMAFE","Inclusion Criteria:\n\n* Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.\n* Women over the age of 18 at the time of signing the informed consent form.\n* Pregnant women with a single gestation between weeks 9 and 15 of gestation who will undergo a chorionic villus biopsy according to the centre's usual clinical practice.\n\nExclusion Criteria:\n\n* Women with multiple pregnancy.\n* Non-evolving pregnancies (including delayed abortion\u002Ffoetal orbit).","FEMALE","18 Years",{"count":134,"type":135},2084,"ESTIMATED","OBSERVATIONAL","Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization that prevents the establishment of a functional maternal-fetal interface has been evidenced. The main objective of this study is to identify molecular markers or aberrant maternal-fetal cell types that can be detected early in the development of the disease in maternal-fetal interface tissue (chorionic villi + decidua) collected during gestational weeks 9 to 15. Maternal-fetal interface biopsy will be collected from women who have a recommendation for aneuploidy testing. The remaining fragment will be used for this study.",[139],"Preeclampsia",[139,141,142,143,144,145,146,147,148,149],"Early onset Preeclampsia (EOPE)","First trimester","Chorionic villi","Pregnancy","Molecular study","Decidua","Maternal-fetal interface","Other pregnancy complications","Omic techniques","2026-04-07",{"date":152,"type":153},"2026-04-13","ACTUAL",{"date":155,"type":153},"2023-11-20",{"date":157,"type":135},"2027-12",{"name":5,"class":6},5]